Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Recombinant glucocerebrosidase

Imiglucerase

Brand names: Cerezyme

Imiglucerase is a recombinant enzyme replacement therapy used for the long-term treatment of type 1 (and selected type 3) Gaucher disease.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It substitutes for deficient glucocerebrosidase, hydrolysing accumulated glucocerebroside in macrophages and reducing organomegaly and haematological complications.

Prescribing in practice

  • Hypersensitivity and infusion-related reactions can occur and may be managed by slowing the infusion, pre-medication or antihistamines as needed.
  • It should be prescribed and supervised by a specialist in Gaucher disease or lysosomal storage disorders.
  • Antibody formation can develop; monitor patients who show reduced response or reactions per current prescribing references.

Monitoring

Monitor haematological parameters, organ volumes and biomarkers of disease activity to assess and adjust therapy.

Counselling the patient

  • Infusions are given on a regular schedule with monitoring for reactions.
  • Report rash, flushing, breathlessness or itching during or after an infusion.
  • Continued treatment is needed to maintain the benefit on blood counts and organ size.

Evidence & guidelines

Enzyme replacement is the established standard of care for type 1 Gaucher disease, supported by long-term registry and trial data.

Reference: NICE highly specialised technology; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Drugs
Pathways